<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003320</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066270</org_study_id>
    <secondary_id>UCLA-HSPC-970101503</secondary_id>
    <secondary_id>UCLA-HSPC-970101502</secondary_id>
    <secondary_id>NCI-G98-1416</secondary_id>
    <nct_id>NCT00003320</nct_id>
  </id_info>
  <brief_title>Radiation Therapy Following Surgery to Remove Brain Metastases</brief_title>
  <official_title>Pilot Study of Adjuvant Fractionated Stereotactic Radiotherapy Following Surgical Removal of Cerebral Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation&#xD;
      therapy after surgery to remove brain metastases may decrease the amount of radiation&#xD;
      required to treat brain metastases.&#xD;
&#xD;
      PURPOSE: Pilot trial to study the effectiveness of radiation therapy following surgery to&#xD;
      remove brain metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the safety and tolerability of focal stereotactic radiotherapy to the&#xD;
      surgical bed following excision of cerebral metastases, as an alternative to whole brain&#xD;
      irradiation. II. Measure the local relapse rate at the surgical site after surgery and&#xD;
      stereotactic radiotherapy in patients with cerebral metastases. III. Measure the regional&#xD;
      relapse rate, in the brain but away from the treated site, following treatment in these&#xD;
      patients.&#xD;
&#xD;
      OUTLINE: All patients undergo surgical removal of their cerebral metastases followed by&#xD;
      adjuvant fractionated stereotactic radiotherapy daily for 5 days. Patients are given up to 5&#xD;
      weeks following surgery to recover and reach the required performance status. Radiotherapy&#xD;
      must commence within 6 weeks of surgery. Patients are followed at 2 weeks after treatment,&#xD;
      monthly for 6 months, every 3 months for the next 18 months, every 6 months for the next&#xD;
      year, and then annually for years 3-5.&#xD;
&#xD;
      PROJECTED ACCRUAL: There will be 20-40 patients accrued into this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1997</start_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">20</enrollment>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiosurgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed cerebral metastases post surgical resection&#xD;
&#xD;
          -  No greater than 3 cerebral metastases postresection&#xD;
&#xD;
          -  Gross resection at operation as documented in operation note and postoperative MRI&#xD;
             Patients must have current surgical sites that have not been previously irradiated&#xD;
&#xD;
          -  No other indication for whole brain irradiation (i.e., multiple untreated metastases&#xD;
             not suitable for single fraction stereotactic radiotherapy, leptomeningeal disease)&#xD;
&#xD;
          -  Age: 18 and over&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
          -  Life expectancy: At least 3 months&#xD;
&#xD;
          -  Prior or concurrent required steroids allowed&#xD;
&#xD;
          -  Prior stereotactic radiotherapy of cerebral metastases allowed provided no prior&#xD;
             irradiation of current surgical sites&#xD;
&#xD;
          -  Prior surgery of cerebral metastases allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe asthma requiring therapy&#xD;
&#xD;
          -  allergy to iodine or contrast media&#xD;
&#xD;
          -  pregnant&#xD;
&#xD;
          -  concurrent chemotherapy&#xD;
&#xD;
          -  prior whole brain irradiation or focal irradiation to current sites of disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith M. Ford, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>February 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2004</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tumors metastatic to brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

